UCD spin-out scoops Ideate Ireland startup competition award

MicroJect, a UCD spin-out, won a runner-up award at the 2026 IDEATE Ireland startup competition. The company is developing a polymer microneedle platform for precise, sustainable drug delivery.
Why it matters
This innovation offers a scalable, patient-friendly alternative to traditional metal needles for vaccines and other therapies.
MicroJect , a University College Dublin (UCD) medtech spin-out supported through NovaUCD, has been announced as the winner of the first runner-up award at the final of the 2026 IDEATE Ireland startup competition.
The competition is focused on uncovering and empowering Ireland's next generation of student entrepreneurs and graduates, helping to turn their brilliant ideas into thriving international businesses.
MicroJect is developing a novel polymer microneedle-based delivery platform that enables safe and consistent intradermal delivery, without the need for conventional metal needles. The company's multi-outlet, multi-depth platform design ensures accurate and precise delivery into the dermis, while reducing patient discomfort, training requirements, and reliance on sharp metal waste.
Designed for scalability and cost-effectiveness through injection moulding, the MicroJect platform supports a wide range of therapies such as allergy diagnosis, vaccines, and high-viscosity formulations, offering a sustainable alternative to traditional injection devices.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in